Soleno Therapeutics (SLNO) Enterprise Value (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Enterprise Value data on file, last reported at -$255.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 11.85% year-over-year to -$255.6 million in Q1 2026; TTM through Mar 2026 was -$255.6 million, a 11.85% increase from a year earlier, with the FY2025 full-year figure at -$305.5 million, down 4.82% from the prior year.
• Enterprise Value for Q1 2026 stood at -$255.6 million, up from -$305.5 million in the prior quarter.
• Over the last five years, Enterprise Value for SLNO reached as high as -$7.9 million in Q1 2023 and fell as low as -$499.0 million in Q3 2025.
• Historically, Enterprise Value has averaged -$172.8 million across 5 years, with a median of -$169.7 million in 2023.
• Across the five-year window, Enterprise Value jumped 72.73% in 2023 and plunged 1793.67% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$14.6 million in 2022, then tumbled by 1062.04% to -$169.7 million in 2023, then sank by 71.76% to -$291.4 million in 2024, then fell by 4.82% to -$305.5 million in 2025, then grew by 16.34% to -$255.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$255.6 million in Q1 2026, -$305.5 million in Q4 2025, and -$499.0 million in Q3 2025.